A study of a GLP-1 medicine, semaglutide, in people with Duchenne muscular dystrophy (DMD).

Who can join: Adults 18+, have Duchenne muscular dystrophy (DMD), BMI 27+.
What you take: Semaglutide, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
How long it lasts: The full study runs about 4 years.
What you get: Costs vary by study. Ask the study team what this one covers, including the study medicine, visits and travel, before you sign the consent form.

This one may not fit you. We check your age, where you live, and the rules each study sets, then show the clinical trials that do.

Check my fit →

Phase Phase 1Sponsor Vanderbilt University Medical CenterDrug semaglutideClass GLP-1 RASites 1 USEnrollment target 30

What this study is for

Primary condition: Duchenne Muscular Dystrophy (DMD).

Full scientific study title: Glucagon-Like Peptide-1 Receptor Agonists to Attenuate Metabolic Risk in Individuals With Duchenne Muscular Dystrophy.

Who can join

Age18 and upSexMaleBMI27 or higher

Adults 18+, have Duchenne muscular dystrophy (DMD), BMI 27+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

Male
Age ≥18 years
BMI ≥ 30 kg/m2 or BMI ≥ 27 kg/m2 with at least one weight-related comorbid condition (e.g., hypertension, T2D, or dyslipidemia).
Clinical phenotype of DMD confirmed with muscle biopsy or genotype

Key exclusion criteria

Type 1 diabetes, uncontrolled type 2 diabetes (HbA1c \>8%) or type 2 diabetes requiring the use of insulin or sulfonylurea.
History of pancreatitis
Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2
History of allergic reaction to semaglutide or medication components
Contraindication to MRI. If unable to tolerate whole body/cardiac MRI but able to undergo lower extremity MRI, the participant may be invited to complete extremity MRI (Aim 1) and not complete MRI for Aim 2/3 (secondary Aims/outcomes)

Where this trial runs

This trial has 1 sites across 1 state. Site contacts are listed for reference. They are not screening through this trial right now.

Tennessee1 site

Vanderbilt University Medical Center
Nashville, Tennessee

Follow this trial

We email you if NCT07642635 changes status, adds new sites in your state, or if a similar trial opens for the same condition.

Timeline

Scheduled start: September 1, 2026. Expected completion: December 2030. Last updated on ClinicalTrials.gov: June 11, 2026.

Official source

Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked September 4, 2026. Confirm the current status there before you contact a site:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this site LinkedIn Contact

Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.